Pediatrix 10-Q Details Q3: $501.4M Revenue, $147.2M Buybacks, Term Loan Due Feb 2027
MD sits 69% above its 52-week low of $16.9.
Summary
Pediatrix's Q3 10-Q backs up the morning's beat with full statements: $501.4M revenue, $220.1M nine-month Adjusted EBITDA, but operating cash flow down to $114.5M while $147.2M went to buybacks and a $178.1M term loan moves current ahead of its February 2027 maturity.
Key Events · Earnings and Guidance · MD
-
Q3 Revenue $501.4M, Adjusted EPS $0.72
Net revenue rose 1.7% to $501.4M from $492.9M; net income was $47.0M, or $0.59 diluted, versus $0.84 a year earlier when a $20.9M divestiture gain inflated the comparison.
-
Nine-Month Adjusted EBITDA $220.1M
Adjusted EBITDA for the nine months was $220.1M versus $209.7M in 2025, leaving roughly $70M-$80M needed in Q4 to hit the raised $290M-$300M full-year range.
-
Operating Cash Flow Falls to $114.5M
Cash from continuing operations dropped from $160.1M a year ago, driven by $74.4M of accounts payable and accrued expense outflows, mostly first-quarter incentive compensation payments.
-
Buybacks Consume $147.2M of Cash
The company repurchased 5.9M shares for $144.7M under the August 2025 program, leaving $21.5M available; cash fell to $311.9M from $375.2M at year-end.
Analysis · MD · Industrial Applications And Services
The headline numbers were already out this morning via the 8-K, but the 10-Q is where the balance sheet and cash flow live, and those carry the real information. Operating cash flow from continuing operations fell to $114.5M for nine months from $160.1M a year ago, driven by $74.4M of incentive compensation payments and weaker receivables collection. Against that, the company spent $147.2M on buybacks in nine months, which is why cash dropped to $311.9M from $375.2M. The $178.1M Term A Loan now sits in current liabilities ahead of its February 2027 maturity, so the $450.0M undrawn revolver is the refinancing lever. Nothing here breaks the thesis, but the cash burn from buybacks plus a near-term debt maturity is the thing to track.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MD was trading at $28.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $16.90 to $30.05. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.